Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT05446142
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 393
- Registration Number
- NCT05419674
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: Platinum-doublet chemotherapy
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 101
- Registration Number
- NCT05407675
- Locations
- 🇺🇸
Local Institution - 0010, Boston, Massachusetts, United States
🇺🇸Local Institution - 0001, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0003, Houston, Texas, United States
A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood
- Conditions
- Healthy
- Interventions
- Drug: BI 1810631 - trial formulation 1 (TF1)Drug: BI 1810631 - new formulation (NF)
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT05380947
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 14
- Registration Number
- NCT05330858
- Locations
- 🇺🇸
Alumis Central Site, Glendale, California, United States
A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 676
- Registration Number
- NCT05208268
- Locations
- 🇰🇷
Site #19, Cheongju, Chungcheongbuk-do, Korea, Republic of
🇰🇷Site #01, Chungju, Chungcheongbuk-do, Korea, Republic of
🇰🇷Site #31, Bucheon, Gyeongji-do, Korea, Republic of
Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05152004
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Helicobacter Pylori Eradication and Follow-up
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 4447
- Registration Number
- NCT05061732
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 504
- Registration Number
- NCT05023577
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Tetracycline Versus Doxycycline for HP Rescue Therapy
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 242
- Registration Number
- NCT05018923
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.